CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI...

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• Heart failure (HF) management requires updated clinical guidance based on recent evidence.
• Key therapeutic areas include valvular heart disease, cardiac amyloidosis, and HF with preserved and reduced ejection fraction.
• Guideline-directed medical therapy and multidisciplinary approaches are crucial for optimal patient care.

Purpose of the Study:

• To review recent clinical trials (post-2017) on selected HF therapies.
• To provide evidence-based recommendations for managing patients considered for novel HF treatments.
• To offer practical tips for healthcare providers treating diverse HF populations.

Main Methods:

• Systematic review of clinical trials published after 2017 focusing on specific HF interventions.
• Analysis of evidence for transcatheter mitral valve repair, transthyretin cardiac amyloidosis treatment, ARNI therapy in HFpEF, and SGLT inhibitors in HF.
• Emphasis on guideline-directed medical therapy and multidisciplinary team roles.

Main Results:

• Transcatheter mitral valve repair requires optimal guideline-directed medical therapy and multidisciplinary evaluation.
• Tafamidis is the first agent to demonstrate outcome improvement in transthyretin cardiac amyloidosis.
• Sacubitril/valsartan may benefit subgroups of HFpEF patients, but further data are needed.
• Sodium-glucose cotransport inhibitors (e.g., dapagliflozin) reduce HF risk, hospitalizations, and cardiovascular death in patients with and without type 2 diabetes, including those with HF with reduced ejection fraction.

Conclusions:

• Healthcare providers should consider cardiac amyloidosis in patients with suggestive clinical signs.
• Tafamidis offers a new therapeutic option for transthyretin cardiac amyloidosis.
• The role of sacubitril/valsartan in HFpEF requires further investigation.
• Sodium-glucose cotransport inhibitors are beneficial for HF prevention and treatment across various patient groups, including those with HF with reduced ejection fraction.